Phase I trial of TRXE 009 (Trilexium)
Phase of Trial: Phase I
Latest Information Update: 17 Nov 2017
At a glance
- Drugs TRXE 009 (Primary)
- Indications Glioma
- Focus Adverse reactions; First in man
- Sponsors Kazia Therapeutics
- 17 Nov 2017 According to a Kazia Therapeutics media release, Novogen changed its name to Kazia Therapeutics.
- 31 Aug 2015 According to a Novogen media release, this trial is expected to begin in 2017.
- 29 Jul 2015 This trial is expected to begin in 2016/2017 according to a Novogen media release.